Hybridoma antibody which inhibits interleukin 2 activity
OwnerSteven Gillisinventor
Life of this patent
Estimating the term…
Abstract
A process for producing anti-IL-2 antibody from hybridoma cells generated by fusing activated, IL-2 immunized, murine lymphocyte cells with neoplastic murine myeloma cells. Fusion is accomplished by mixing the two cell lines together in the presence of a fusing agent. After fusion, the hybridoma cells are cultured in vitro in a supplemented tissue culture medium to thereby produce anti-IL-2 antibody. Also, the hybridoma cells are cloned by a limiting dilution procedure to isolate even more potent sources of anti-IL-2 antibody. Anti-IL-2 antibody is then purified from either tissue culture medium conditioned by hybridoma cells, or from peritoneal ascites of mice challenged with hybridoma cells.
Claims69
A process for producing a hybridoma antibody which inhibits IL-2 activity, comprising:
- immunizing murine B-lymphocyte cells with IL-2;
- activating said immunized murine B-lymphocyte cells with a B-cell mitogen;
- fusing said activated murine B-lymphocyte cells with murine myeloma cells to form hybridoma anti-IL-2 antibody producing cells
- cultivating said anti-IL-2 antibody producing cells;
- and
- recovering the anti-IL-2 antibody produced by said anti-IL-2 antibody producing cells.
Hybrid anti-IL-2 antibody producing cells formed by:
- immunizing murine B-lymphocyte cells with IL-2;
- activating said immunized murine B-lymphocyte cells with a B-cell mitogen and fusing said activated murine B-lymphocyte cells with murine myeloma cells.
A process for producing anti-IL-2 antibody from a hybrid murine cell line, comprising culturing in a tissue culture medium hybrid cells produced by fusing neoplastic murine myeloma cells with IL-2 immunized murine cells which have been later activated with a B-cell mitogen;
- and then recovering the anti-IL-2 antibody from the culture.
Dependencies are inferred from the claim text.